Xencor, Inc. (NASDAQ:XNCR) Director Alan Bruce Montgomery Sells 2,215 Shares

Xencor, Inc. (NASDAQ:XNCR - Get Free Report) Director Alan Bruce Montgomery sold 2,215 shares of the company's stock in a transaction dated Monday, June 16th. The shares were sold at an average price of $9.22, for a total transaction of $20,422.30. Following the transaction, the director now directly owns 20,611 shares of the company's stock, valued at $190,033.42. This represents a 9.70% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Xencor Price Performance

Shares of NASDAQ:XNCR traded up $0.05 on Thursday, hitting $8.36. The stock had a trading volume of 835,269 shares, compared to its average volume of 667,672. The firm's 50 day moving average price is $9.07 and its 200-day moving average price is $14.70. The company has a debt-to-equity ratio of 0.16, a quick ratio of 5.89 and a current ratio of 5.89. Xencor, Inc. has a twelve month low of $7.16 and a twelve month high of $27.24. The company has a market capitalization of $594.98 million, a price-to-earnings ratio of -2.73 and a beta of 0.87.

Xencor (NASDAQ:XNCR - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The biopharmaceutical company reported ($0.66) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.60) by ($0.06). The firm had revenue of $32.73 million for the quarter, compared to the consensus estimate of $23.44 million. Xencor had a negative net margin of 181.17% and a negative return on equity of 31.94%. The company's revenue for the quarter was up 104.6% on a year-over-year basis. During the same period in the prior year, the business earned ($1.11) earnings per share. On average, equities research analysts predict that Xencor, Inc. will post -3.68 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the company. RTW Investments LP grew its position in Xencor by 317.9% during the 4th quarter. RTW Investments LP now owns 2,402,883 shares of the biopharmaceutical company's stock worth $55,218,000 after acquiring an additional 1,827,883 shares during the last quarter. BVF Inc. IL boosted its stake in Xencor by 169.3% in the fourth quarter. BVF Inc. IL now owns 2,288,760 shares of the biopharmaceutical company's stock worth $52,596,000 after purchasing an additional 1,438,760 shares in the last quarter. Braidwell LP grew its holdings in shares of Xencor by 169.0% during the first quarter. Braidwell LP now owns 1,655,690 shares of the biopharmaceutical company's stock worth $17,617,000 after purchasing an additional 1,040,159 shares during the last quarter. Primecap Management Co. CA increased its stake in shares of Xencor by 8.6% in the first quarter. Primecap Management Co. CA now owns 9,761,012 shares of the biopharmaceutical company's stock valued at $103,857,000 after buying an additional 776,580 shares in the last quarter. Finally, Nuveen Asset Management LLC raised its holdings in shares of Xencor by 452.4% in the fourth quarter. Nuveen Asset Management LLC now owns 837,082 shares of the biopharmaceutical company's stock valued at $19,236,000 after buying an additional 685,557 shares during the last quarter.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on XNCR shares. William Blair started coverage on Xencor in a report on Monday, April 21st. They issued an "outperform" rating for the company. Wall Street Zen cut Xencor from a "hold" rating to a "sell" rating in a research report on Friday, March 14th. Wedbush reissued an "outperform" rating and issued a $31.00 price target on shares of Xencor in a report on Wednesday, April 30th. Barclays decreased their target price on shares of Xencor from $22.00 to $6.00 and set an "underweight" rating on the stock in a research report on Thursday, May 8th. Finally, Wells Fargo & Company lowered their target price on shares of Xencor from $37.00 to $33.00 and set an "overweight" rating on the stock in a research note on Friday, February 28th. Two investment analysts have rated the stock with a sell rating and seven have issued a buy rating to the company's stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $28.00.

About Xencor

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.